Scribble

Price Momentum

FRNM is trading near the top of its 52-week range and below its 200-day simple moving average.
Price change

The price of FRNM shares has decreased $0.71 since the market last closed. This is a 6.59% drop.
Last closed at $10.06.

Key terms

Freenome, Inc. operates as a biotechnology company. It engages in the development of an early cancer detection platform. The company was founded in 2014 and is headquartered in New York, NY.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Market cap: $103.75M

A market capitalization up to $300 million places FRNM in the micro-capitalization category.

Key terms

Smart score

Jul 27, 2026 8:28am ET Freenome’s SimpleScreen CRC Test Gains FDA Approval by TipRanks Jul 27, 2026 8:16am ET Freenome, Abbott announce FDA approval of SimpleScreen CRC by TipRanks Jul 24, 2026 6:37am ET Freenome Completes De-SPAC, Begins Trading on Nasdaq by TipRanks

Jul 27, 2026 8:00am ET FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. by GlobeNewswire

1-year income & revenue

FRNM total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
Net income: $837.47K (1Y), -$114.94K (Q2)

Net Income decreased 56.16% since last year and decreased 122.12% since last quarter.
Earnings per share: $0.08 (1Y), -$0.01 (Q2)

EPS decreased 56.14% since last year and decreased 136.17% since last quarter.

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

How competitors are chosen

FRNM's competitors are included in the Health Technology sector and Biotechnology group
Market cap: $103.75M

A market capitalization up to $300 million places FRNM in the micro-capitalization category.